OncoMatch

OncoMatch/Clinical Trials/NCT07250542

A Clinical Study on the Efficacy and Safety of Fasudil Hydrochloride Combined With Immunotherapy in the Treatment of Metastatic Castration-resistant Prostate Cancer

Is NCT07250542 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fasudil hydrochloride combined with immunotherapy for prostate cancer.

Phase 2Recruitingbaotai LiangNCT07250542Data as of May 2026

Treatment: Fasudil hydrochloride combined with immunotherapyCarrying out clinical trials of salbutamol hydrochloride combined with immunotherapy and castration for the treatment of prostate cancer is of great significance. Firstly, it can verify the efficacy and safety of this combination in the treatment of prostate cancer, providing a scientific basis for its clinical application. Secondly, through clinical trials, the mechanism of action of salbutamol hydrochloride combined with immunotherapy can be further studied. Finally, this clinical trial can further expand the treatment strategies for prostate cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Prior therapy

Min 2 prior lines

Must have received: chemotherapy (docetaxel)

failed at least one chemotherapy regimen containing docetaxel

Must have received: novel endocrine therapy

failed at least one standard novel endocrine therapy

Lab requirements

Kidney function

Serum creatinine < 1.5 mg/dl or creatinine clearance rate ≥ 60 cc/min

Liver function

Total bilirubin < 1.5x ULN, ALT/AST < 2x ULN

Abnormal liver function: Total bilirubin in blood is less than 1.5 times the upper limit of normal value, and the ratio of blood ALT to AST is less than 2 times the upper limit of normal value; Abnormal kidney function: Serum creatinine is less than 1.5 mg/dl or the creatinine clearance rate is greater than or equal to 60 cc/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify